ERYTECH Pharma receives € 7 Million from OSEO to lead the TEDAC personalized medicine project in cancer

ERYTECH Pharma is pleased to announce that it received a total of € 6.95 million in support from the Strategic Industrial Innovation program of the French public organization OSEO to lead the TEDAC project (Therapeutic Enzymes to Deplete Amino acids to treat Cancers resistant to radio/chemotherapy).

Menu